Cognitive and/or motor deficiencies associated with Alzheimer's are treated using 2-amino substituted nicotinamides or their pharmaceutically acceptable salts.
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
C07D 213/04 - Composés hétérocycliques contenant des cycles à six chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle et avec au moins trois doubles liaisons entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques comportant trois liaisons doubles ne comportant pas de liaison entre l'atome d'azote du cycle et un chaînon non cyclique ou ne comportant que des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle
Motor skill deficits and cognitive deficits associated with stroke and secondary neuronal cell death are ameliorated by treatment with pharmaceutically acceptable salts of 2‑amino substituted nicotinamides.
A61K 31/4025 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil non condensés et contenant d'autres hétérocycles, p. ex. cromakalim
The present disclosure provides multipotent neural stem cells that express platelet derived growth factor (PDGF) receptor and the use of such cells to produce oligodendrocytic cells for the treatment of neurodegenerative diseases or trauma to the nervous system.
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
A61K 31/497 - Pyrazines non condensées contenant d'autres hétérocycles
C07D 213/44 - Radicaux substitués par des atomes d'oxygène, de soufre ou d'azote liés par des liaisons doubles ou par deux de ces atomes liés au même atome de carbone par des liaisons simples
6.
AMELIORATION OF NEURAL DEFICITS ASSOCIATED WITH DIABETES
C07D 213/78 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
The present disclosure provides a human neural stem cell comprising an exogenous polynucleotide coding for a growth factor such as IGF-1. Also disclosed are methods of using the human neural stem cells for the treatment of neurodegenerative diseases or disorders including, for example, ALS.
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C07K 14/65 - Facteurs de croissance analogues à l'insuline, c.-à-d. somatomédines, p. ex. IGF-1, IGF-2
8.
Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof
The present disclosure provides a human neural stem cell comprising an exogenous polynucleotide coding for a growth factor such as IGF-1. Also disclosed are methods of using the human neural stem cells for the treatment of neurodegenerative diseases or disorders including, for example, ALS.
A61K 35/30 - NerfsCerveauYeuxCellules cornéennesLiquide céphalorachidienCellules souches neuronalesCellules précurseurs neuronalesCellules glialesOligodendrocytesCellules de SchwannAstrogliesAstrocytesPlexus choroïdeTissu de moelle épinière
A61K 38/30 - Facteurs de croissance analogues à l'insuline, c.-à-d. somatomédines, p. ex. IGF-1, IGF-2
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
9.
STABLE NEURAL STEM CELLS COMPRISING AN EXOGENOUS POLYNUCLEOTIDE CODING FOR A GROWTH FACTOR AND METHODS OF USE THEREOF
The present disclosure provides a human neural stem cell comprising an exogenous polynucleotide coding for a growth factor such as IGF-1. Also disclosed are methods of using the human neural stem cells for the treatment of neurodegenerative diseases or disorders including, for example, ALS. The present disclosure generally relates to a human neural stem cell comprising an exogenous polynucleotide coding for a growth factor including, for example, a neurotrophic factor. In an embodiment, the growth factor is stably expressed by the human neural stem cell. Such human neural stem cells may be used for the treatment of a neurodegenerative disease or disorder in a subject in need thereof (e.g., a human subject having a neurodegenerative disease or disorder).
A61K 35/30 - NerfsCerveauYeuxCellules cornéennesLiquide céphalorachidienCellules souches neuronalesCellules précurseurs neuronalesCellules glialesOligodendrocytesCellules de SchwannAstrogliesAstrocytesPlexus choroïdeTissu de moelle épinière
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C07K 14/475 - Facteurs de croissanceRégulateurs de croissance
C07K 14/65 - Facteurs de croissance analogues à l'insuline, c.-à-d. somatomédines, p. ex. IGF-1, IGF-2
The present disclosure provides a human neural stem cell comprising an exogenous polynucleotide coding for a growth factor such as IGF-1. Also disclosed are methods of using the human neural stem cells for the treatment of neurodegenerative diseases or disorders including, for example, ALS. The present disclosure generally relates to a human neural stem cell comprising an exogenous polynucleotide coding for a growth factor including, for example, a neurotrophic factor. In an embodiment, the growth factor is stably expressed by the human neural stem cell. Such human neural stem cells may be used for the treatment of a neurodegenerative disease or disorder in a subject in need thereof (e.g., a human subject having a neurodegenerative disease or disorder).
Although it is known that certain benzylpiperazine-aminopyridines or open chain forms thereof are effective in stimulating neural growth in in vitro tests, it has now been surprisingly found that administering these compounds in a dosage range of 10 mg/day - 130 mg/day over 25-35 days is effective in treating Major Depressive Disorder (MDD) such that statistically significant results can be obtained with samples of only six subjects.
Although it is known that certain benzylpiperazine-aminopyridines or open chain forms thereof are effective in stimulating neural growth in in vitro tests, it has now been surprisingly found that administering these compounds in a dosage range of 10 mg/day - 130 mg/day over 25-35 days is effective in treating Major Depressive Disorder (MDD) such that statistically significant results can be obtained with samples of only six subjects.
REGENTS OF THE UNIVERSITY OF CALIFORNIA, IRVINE (USA)
Inventeur(s)
Johe, Karl K.
Limoli, Charles L.
Hazel, Thomas G.
Hefferan, Michael
Acharya, Munjal M.
Abrégé
The disclosure relates generally to methods of treating a subject with a cognitive dysfunction by administering to the brain of the subject an effective amount of spinal cord neural stem cells. The present disclosure provides methods for treating a subject with a cognitive dysfunction including, for example, a subject that has received radiotherapy for the treatment of a primary or secondary brain tumor. Such methods may be useful for treating symptoms resulting from exposure to radiation or symptoms of neurological diseases. In one aspect, the present disclosure provides methods for treating a subject with a cognitive dysfunction, for example, a human, by introducing a therapeutically effective amount of spinal cord-derived neural stem cells to one or more areas of the subject's brain (e.g., hippocampus).
COMPOSITIONS COMPRISING AN IMMUNOSUPPRESSIVE DRUG AND/OR NEURAL STEM CELLS AND METHODS OF USING SAME FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AND/OR DISORDERS
The present disclosure relates generally to compositions and methods for treating a subject with a neurodegenerative disease and/or disorder) such as an injured spinal cord, stroke, or ALS. Such methods include administering to a subject, in need thereof, a therapeutically effective amount of one or more immunosuppressive drugs and/or a therapeutically effective amount of neural stem cells. Treatment with the one or more immunosuppressive drugs and neural stem cells may be effective to ameliorate one or more signs or symptoms of a neurodegenerative disease and/or disorder such as an injured spinal cord, stroke, or ALS.
The present disclosure provides methods for the treatment of neurological diseases/disorders using neural stem cells (NSCs) obtained from a spinal cord tissue. The methods may include the use of a NSC population to treat a neurological disease/disorder of the brain. Such methods may include introducing exogenously cultured and expanded NSCs into the brain, which differentiate into neurons capable of integrating in vivo into the brain tissue in a sufficient manner to ameliorate the symptoms associated with the neurological disease/disorder.
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir de micro-organismes, de virus, de champignons microscopiques ou d'animaux, p. ex. enzymes ou produits de fermentation
A61K 35/30 - NerfsCerveauYeuxCellules cornéennesLiquide céphalorachidienCellules souches neuronalesCellules précurseurs neuronalesCellules glialesOligodendrocytesCellules de SchwannAstrogliesAstrocytesPlexus choroïdeTissu de moelle épinière
16.
METHODS FOR TREATING AND/OR REVERSING NEURODEGENERATIVE DISEASES AND/OR DISORDERS
The present disclosure provides methods for the treatment of neurological diseases/disorders using neural stem cells (NSCs) obtained from a spinal cord tissue. The methods may include the use of a NSC population to treat a neurological disease/disorder of the brain. Such methods may include introducing exogenously cultured and expanded NSCs into the brain, which differentiate into neurons capable of integrating in vivo into the brain tissue in a sufficient manner to ameliorate the symptoms associated with the neurological disease/disorder.
The invention describes an improved synthesis for piperazine derivatized with nicotinic acid and a benzyl moiety. The product compounds are useful for treatment of neurological conditions.
The invention describes an improved synthesis for piperazine derivatized with nicotinic acid and a benzyl moiety. The product compounds are useful for treatment of neurological conditions.
A method of treating neurodegenerative conditions is provided. Neural stem cells may be implanted at and/or remote from a region of neuron degeneration. The methods can include isolating neural stem cells from regions where specific types of neurons corresponding to the neurons to be replaced are generated. The methods can include isolating neural stem cells secreting growth factors affecting the growth and/or regeneration of specific types of neuron. In this invention, we disclose a method of treating such disorders, including several neurodegenerative disorders arising from the lack of cells that produce particular neurotransmitters in neural circuitry by transplanting exogenously cultured and expanded neural progenitors which, upon transplantation into a neural tissue, differentiate into neurons capable of integrating and producing neurotransmitters in sufficient quantities and in a sufficient manner to overcome the symptoms associated with the neurodegeneration.
brevets
